Stopping a proton pump inhibitor (PPI) during a C. diff infection reduces the chance of the infection coming back. Patients who continue PPIs have a recurrence rate of about 24%, compared to 18% for those who stop. The relationship between these acid-suppressing medications and C. diff is driven primarily by changes PPIs cause in the gut microbiome, making the intestinal environment more hospitable to the bacteria.
That said, the recommendation isn’t absolute. If you have a genuine medical need for your PPI, current guidelines from the American College of Gastroenterology say you shouldn’t discontinue it just because of a C. diff diagnosis. The key question is whether you still have a valid reason to be on the medication in the first place.
How PPIs Change Your Gut Environment
The connection between PPIs and C. diff goes beyond simple stomach acid suppression. Researchers initially assumed the link was straightforward: PPIs raise stomach pH, allowing C. diff spores to survive the acid barrier and reach the intestines. But lab studies found that C. diff spores actually survive in acidic gastric contents just fine on their own. The spores are hardy enough to pass through the stomach regardless of acid levels.
The real damage happens further downstream. PPI use is associated with a significant decrease in overall gut bacterial diversity, with changes affecting roughly 20% of bacterial species in the gut. Specifically, PPIs reduce populations of beneficial bacteria like Bifidobacterium and members of the Ruminococcaceae family, both of which help keep C. diff in check. At the same time, PPIs increase populations of potentially harmful species, including E. coli, Enterococcus, Streptococcus, and Staphylococcus.
This shift happens because reducing stomach acid allows more oral bacteria to survive the trip into the gut, essentially seeding the lower digestive tract with microbes that don’t normally thrive there. The result is a less diverse, less resilient microbial community that is more vulnerable to C. diff colonization and overgrowth. When you’re already fighting a C. diff infection, continuing to suppress that microbial diversity works against your recovery.
The Numbers Behind the Risk
A pooled analysis of 50 studies found that PPI users have about 26% higher odds of developing a C. diff infection compared to non-users. That risk holds whether you’re in a hospital or in the community, though hospital-acquired infections show a slightly stronger association (29% increased risk on general wards, and potentially higher in intensive care units).
The recurrence picture is even more concerning. A systematic review combining multiple adjusted studies found that patients who continued PPIs after an initial C. diff episode had 49% higher odds of the infection returning. The unadjusted numbers were starker: 69% higher odds. For a disease where recurrence already plagues a significant minority of patients, that’s a meaningful increase in risk.
Duration matters too. Hospitalized patients using acid-suppressing drugs for more than 14 days had roughly 3.7 times the risk of C. diff compared to those using them for less than a week. This dose-response pattern strengthens the case that the drugs themselves are contributing to the problem, not just coinciding with sicker patients.
PPIs vs. H2 Blockers
If you need some form of acid suppression, the type of medication you use makes a difference. A large study comparing over 63,000 PPI users with nearly 70,000 patients on H2 receptor antagonists (like famotidine) found that the C. diff rate in the PPI group was more than three times higher: 1.6 per 10,000 person-days versus 0.5. After adjusting for other factors, PPI users still had about 2.5 times the risk.
This held true across high-risk subgroups, including patients on antibiotics, those in the ICU, and immunocompromised individuals. H2 blockers suppress acid less aggressively than PPIs, which likely explains the difference. For patients who need some acid control but are dealing with or recovering from C. diff, switching to an H2 blocker is a practical middle ground worth discussing with your care team.
When PPIs Should Continue Despite C. Diff
Not every PPI prescription should be stopped. The ACG guidelines are clear: if there’s an appropriate indication for the PPI, don’t discontinue it solely because of a C. diff infection. Conditions like Barrett’s esophagus, severe erosive esophagitis, or a history of bleeding ulcers represent situations where stopping acid suppression could cause serious harm.
The patients who benefit most from stopping are those who were put on a PPI for a vague or outdated reason, which is surprisingly common. Studies consistently find that a large proportion of PPI prescriptions in hospitals and outpatient settings lack a strong clinical justification. Many people start a PPI during a hospital stay for stress ulcer prevention and simply never stop taking it. Others were prescribed one for mild heartburn that could be managed with lifestyle changes or a less potent medication. A C. diff diagnosis is often the trigger that prompts a closer look at whether the PPI is truly necessary.
The practical approach is a risk-benefit conversation. If your reason for taking a PPI is serious and well-documented, the benefit of continuing likely outweighs the added recurrence risk. If the reason is unclear, mild, or no longer relevant, stopping or stepping down to an H2 blocker tilts the balance toward better C. diff outcomes.